Arsenic trioxide loaded PLGA nanoparticles inhibits formation of malignant ascites of pancreatic carcinoma

( views:, downloads: )
Author:
HUANG Kai-hong()
LIU Jian-hua()
LI Xue-xian()
CHEN Yin-ting()
XU Li-shu()
CHEN Qi-kui()
ZHU Zhao-hua()
REN Shan()
Journal Title:
CHINESE JOURNAL OF PANCREATOLOGY
Issue:
Volume 7, Issue 05, 2007
DOI:
Key Word:

Abstract:

  • [1]郭萌,赵倩,黄莺,等.三氧化二砷治疗急性早幼粒细胞性白血病研究进展.中国药物与临床,2003,3:291-294.
  • [2]张晨,凌昌全.三氧化二砷抗实体肿瘤的研究概况.第二军医大学学报,2003,24:440-443.
  • [3]Siegel SJ,Kahn JB,Metzger K,et al.Effect of drug type on the degradation rate of PLGA matrices.Eur J Pharm Biopharm,2006,64:287-293.
  • [4]Otsuka H,Nagasaki Y,Kataoka K.PEGylated nanoparticles for biological and pharmaceutical applications.Adv Drug Deliv Rev,2003,55:403-419.
  • [5]黄开红,朱兆华,刘建化,等.聚乳酸载药纳米微粒制备及其释药效能.癌症,2005,24:1023-1026.
  • [6]Yoshiji H,Kuriyama S,Hickin DJ,et al.The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model.Hepatology,2001,33:841-847.
  • [7]Cohen MH,Hirschfeld S,Flamm Honig S,et al.Drug approval summaries:arsenic trioxide,tamoxifen citrate,anastrazole,paclitaxel,bexarotene.Oncologist,2001,6:4-11.
  • [8]王希路,张倜,王绍山,等.三氧化二砷抗肝癌作用及其肾毒性作用的实验研究.中华实验外科杂志,2002,19:114-116.
  • [9]吴楠,胡龙虎,周晋,等.三氧化二砷注射液对人体的不良反应分级及其防治对策.中华内科杂志,2006,45:310-313.
  • [10]Kabanov AV.Polymer genomics:an insight into pharmacology and toxicology of nanomedicines.Adv Drug Deliv Rev,2006,58:1597-1621.
  • [11]Memisoglu-Bilensoy E,Dogan AL,Hincal AA.Cytotoxic evaluation of injectable cyclodextrin nanoparticles.J Pharm Pharmacol,2006,58:585-589.
  • [12]刘扬,吕万良,张强.脂质体及纳米粒药物递送系统的研究进展.中国医学科学院学报,2006,28:583-589.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn